HK15293A - Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations - Google Patents

Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations

Info

Publication number
HK15293A
HK15293A HK152/93A HK15293A HK15293A HK 15293 A HK15293 A HK 15293A HK 152/93 A HK152/93 A HK 152/93A HK 15293 A HK15293 A HK 15293A HK 15293 A HK15293 A HK 15293A
Authority
HK
Hong Kong
Prior art keywords
preparation
biologically active
pharmaceutical preparations
active fragments
antihemophilic factor
Prior art date
Application number
HK152/93A
Other languages
English (en)
Inventor
Lars-Olof Andersson
Nanna Forsman
Kerstin Ebba Ingrid Larsen
Annelie Birgitta Lundin
Bohdan Paviu
Inga Helena Sandberg
Karin Margareta Sewerin
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20359353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK15293(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of HK15293A publication Critical patent/HK15293A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D31/00—Protective arrangements for foundations or foundation structures; Ground foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Structural Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Civil Engineering (AREA)
  • Paleontology (AREA)
  • Mining & Mineral Resources (AREA)
  • Hydrology & Water Resources (AREA)
  • Environmental & Geological Engineering (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK152/93A 1985-03-05 1993-02-25 Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations HK15293A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof

Publications (1)

Publication Number Publication Date
HK15293A true HK15293A (en) 1993-03-05

Family

ID=20359353

Family Applications (1)

Application Number Title Priority Date Filing Date
HK152/93A HK15293A (en) 1985-03-05 1993-02-25 Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations

Country Status (10)

Country Link
US (2) US4749780A (de)
EP (1) EP0197901B1 (de)
JP (1) JPS61205219A (de)
AT (1) ATE65505T1 (de)
CA (1) CA1341497C (de)
DE (1) DE3680368D1 (de)
DK (1) DK164282B (de)
HK (1) HK15293A (de)
SE (1) SE8501050D0 (de)
SG (1) SG1893G (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
JP2593500B2 (ja) * 1986-06-24 1997-03-26 ノルデイスク ゲントフテ エー／エス ▲ｖｉｉｉ▼因子フラグメントの凝固活性複合物の製造方法
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
AU662056B2 (en) * 1992-04-06 1995-08-17 Pressmaster Tool Ab A crimping tool
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
EP2202242A1 (de) 1996-04-24 2010-06-30 The Regents of The University of Michigan Gegen Inaktivierung resistenter Faktor VIII
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
WO1997049730A1 (de) * 1996-06-24 1997-12-31 Max-Planck-Institut Für Physiologische Und Klinische Forschung Kerckhoff-Klinik Gmbh Verfahren zur affinitätschromatographischen aufreinigung von faktor viii
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
EP1038959A1 (de) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP1233064A1 (de) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
DE60234193D1 (de) * 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
US7220718B2 (en) 2001-08-03 2007-05-22 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
EP2574677B1 (de) 2007-12-27 2017-09-13 Baxalta GmbH Zellkulturverfahren
EP2704688B1 (de) * 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleatzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
US4650858A (en) * 1983-03-21 1987-03-17 Nordisk Gentofte A/S Concentrate of the antihemophilic factor VIII and a process for producing it
NO167533C (no) * 1983-03-31 1991-11-13 Scripps Clinic Res Fremgangsmaate ved fremstilling av faktor viii koagulerende polypeptider og monoklonale antistoffer overfor disse.
DE10399010I1 (de) * 1984-01-12 2003-10-23 Chiron Corp. F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof

Also Published As

Publication number Publication date
DE3680368D1 (de) 1991-08-29
CA1341497C (en) 2006-02-14
JPH0547524B2 (de) 1993-07-19
SG1893G (en) 1993-06-11
DK85786A (da) 1986-09-06
DK164282B (da) 1992-06-01
ATE65505T1 (de) 1991-08-15
US4749780A (en) 1988-06-07
EP0197901B1 (de) 1991-07-24
US4877614A (en) 1989-10-31
DK85786D0 (da) 1986-02-25
SE8501050D0 (sv) 1985-03-05
EP0197901A1 (de) 1986-10-15
JPS61205219A (ja) 1986-09-11

Similar Documents

Publication Publication Date Title
HK15293A (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
GEP20084347B (en) New derivatives of diphosphonic acid, method for their preparation and medicamentous form containing them
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CS553490A3 (en) Transdermal therapeutic system
EP0859627A4 (de) Peptid-immitierende substanzen in der krebstherapie
ES2000743A6 (es) Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos.
HU895785D0 (en) Process for the preparation of compositions and medical preparations containing acid-resistent fibroplast growth activator for treating gastrointestinal ulcer
IL81573A (en) Pharmaceutical preparations for the treatment of psoriasis containing tamoxifen
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
HU907959D0 (en) Medical preparations
ZA87472B (en) System for delivering drug with enhanced bioacceptability
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
EP0324802A4 (en) Method for the treatment of body tissues and the administration of drugs thereto
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
HU902004D0 (en) New trombolitic preparations
BG44709A3 (bg) Метод за получаване на 9-хлор-1,5-бензотиазепинови производни
AU564439B2 (en) Pharmaceutical compositions containing l-alpha- glycerylphosphorylcholine
EP0180737A3 (en) Use of preparations containing gamma-interferon (ifn-gamma) for treating rheumatic diseases
HU896052D0 (en) Process for the preparation of peptides with t-cell suppressoral activity and medical preparations containing such peptides
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
ZA885625B (en) Therapeutic agents containing enantiomers of propafenone
ZA868813B (en) Dna sequence,recombinant dna and process for producing human tissue plasminogen activator

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)